VINORELBINE Side Effects

6977260-6 | Alopecia, Asthenia, Granulocytopenia, Infection, Thrombocytopenia
on Sep 01, 2010 Female patient from SWITZERLAND , weighting 143.3 lb, was treated with Vinorelbine (View Usage). Patient experienced the following unwanted or unexpected effects: alopecia, asthenia, granulocytopenia, infection (What is infection?), thrombocytopenia. Vinorelbine dosage: Cycles 1 And 2: 25 Rng/m2 And Cycles 3 And 4:17 Mg/m2. During the same period patient was treated with CISPLATIN (90 Mg/m2, 1xper Cycle) (View Cisplatin Review and Cisplatin Label ), VINCA ALKALOIDS AND ANALOGUES (5 Mg, Tid) (View Vinca Alkaloids And Analogues Review and Vinca Alkaloids And Analogues Label ), PANTOPRAZOLE SODIUM (Unk) (View Pantoprazole Sodium Review and Pantoprazole Sodium Label ), CLEXANE (Unk) (View Clexane Review and Clexane Label ), ESCITALOPRAM OXALATE (Unk) (View Escitalopram Oxalate Review and Escitalopram Oxalate Label ), HALDOL (Unk) (View Haldol Review and Haldol Label ), AMLODIPINE (Unk) (View Amlodipine Review and Amlodipine Label ), ISCADOR (Unk) (View Iscador Review and Iscador Label ).

6816594-2 | Asthenia, Blood Pressure Decreased, Bradycardia, Cholestasis, Confusional State, Cyanosis, Cytolytic Hepatitis, Dehydration, Diarrhoea
Patient was taking Vinorelbine (View Usage). Patient had the following side effects: asthenia, blood pressure decreased, bradycardia, cholestasis, confusional state, cyanosis, cytolytic hepatitis, dehydration, diarrhoea on Jun 16, 2010 from FRANCE Additional patient health information: Female patient , 73 years of age, weighting 94.80 lb, was diagnosed with breast cancer (What is breast cancer?) and. Vinorelbine dosage: 32 Mg; Iv. During the same period patient was treated with LAPATINIB (1250 Mg; Po) (View Lapatinib Review and Lapatinib Label ), TAREG (View Tareg Review and Tareg Label ), CORTANCYL (View Cortancyl Review and Cortancyl Label ), ZOLPIDEM (View Zolpidem Review and Zolpidem Label ), ZOMETA (View Zometa Review and Zometa Label ), ALPRAZOLAM (View Alprazolam Review and Alprazolam Label ). Patient was hospitalized.

6814595-1 | Cholelithiasis, Gamma-glutamyltransferase Increased, Hepatic Pain
Adverse event was reported on Jun 22, 2010 by a Female patient taking Vinorelbine (View Usage) (Dosage: 40 Mg Iv) was diagnosed with breast cancer metastatic and. Location: FRANCE , 44 years of age, weighting 224.9 lb, After Vinorelbine was administered, patient had the following side effects: cholelithiasis, gamma-glutamyltransferase increased, hepatic pain. During the same period patient was treated with LAPATINIB (1000 Mg Po) (View Lapatinib Review and Lapatinib Label ), ACETAMINOPHEN (View Acetaminophen Review and Acetaminophen Label ), INNOHEP. MFR: NOT SPECIFIED (View Innohep. Mfr: Not Specified Review and Innohep. Mfr: Not Specified Label ). Patient was hospitalized.

6791069-8 | Condition Aggravated, Diarrhoea, Faecal Incontinence, Hallucination, Pain
on Jun 23, 2010 Female patient from UNITED STATES , weighting 154.3 lb, was diagnosed with breast cancer metastatic and was treated with Vinorelbine (View Usage). Patient experienced the following unwanted or unexpected effects: condition aggravated, diarrhoea, faecal incontinence, hallucination, pain (What is pain?). Vinorelbine dosage: 20mg/m2 = 35.2mg Weekly Iv Bolus. During the same period patient was treated with SORAFENIB 200MG (200mg Bid Po) (View Sorafenib 200mg Review and Sorafenib 200mg Label ), ATIVAN LORAZEPA (View Ativan-lorazepa Review and Ativan-lorazepa Label ), COMPAZINE (View Compazine Review and Compazine Label ), MEGACE (View Megace Review and Megace Label ), METHADONE (View Methadone Review and Methadone Label ), NIFEDICAL (View Nifedical Review and Nifedical Label ), NORCO HYDROCODONE/ ACETAMINOPHEN (View Norco - Hydrocodone/ Acetaminophen- Review and Norco - Hydrocodone/ Acetaminophen- Label ), OXYCONTIN (View Oxycontin Review and Oxycontin Label ). Patient was hospitalized.


6738953-9 | Rash
on May 11, 2010 Female patient from UNITED STATES , 54 years of age, was treated with Vinorelbine (View Usage). Patient had the following side effects: rash (What is rash?). Vinorelbine dosage: 25 Mg/m2 Iv. During the same period patient was treated with TRASTUZUMAB (View Trastuzumab Review and Trastuzumab Label ).

6734162-8 | Cough, Dyspnoea, Neutropenic Sepsis, Pneumonia Klebsiella
Patient was taking Vinorelbine (View Usage). After Vinorelbine was administered, patient had the following side effects: cough, dyspnoea, neutropenic sepsis, pneumonia klebsiella on May 12, 2010 from UNITED KINGDOM Additional patient health information: Female patient , 71 years of age, was diagnosed with adenocarcinoma and. Vinorelbine dosage: Unk. During the same period patient was treated with CISPLATIN (Unk) (View Cisplatin Review and Cisplatin Label ). Patient was hospitalized.

6700151-2 | Chest Pain, Pleuritic Pain
Adverse event was reported on Apr 15, 2010 by a Female patient taking Vinorelbine (View Usage) (Dosage: ) was diagnosed with non-small cell lung cancer and. Location: UNITED KINGDOM , 61 years of age, Patient experienced the following unwanted or unexpected effects: chest pain (What is chest pain?), pleuritic pain. During the same period patient was treated with SIMVASTATIN (View Simvastatin Review and Simvastatin Label ), LISINOPRIL (View Lisinopril Review and Lisinopril Label ), AMLODIPINE (View Amlodipine Review and Amlodipine Label ), CHLORPHENAMINE (View Chlorphenamine Review and Chlorphenamine Label ), CIPROPLOXACIN (View Ciproploxacin Review and Ciproploxacin Label ), METOCLOPRAMIDE HYDROCHLORIDE (View Metoclopramide Hydrochloride Review and Metoclopramide Hydrochloride Label ). Patient was hospitalized.

6694659-6 | Chest Pain, Pleuritic Pain
on Apr 15, 2010 Female patient from UNITED KINGDOM , 61 years of age, was diagnosed with non-small cell lung cancer and was treated with Vinorelbine (View Usage). Patient had the following side effects: chest pain (What is chest pain?), pleuritic pain. Vinorelbine dosage: . During the same period patient was treated with AMLODIPINE (5 Mg, Unk) (View Amlodipine Review and Amlodipine Label ), CHLORPHENAMINE (4 Mg, Unk) (View Chlorphenamine Review and Chlorphenamine Label ), CIPROFLOXACIN (View Ciprofloxacin Review and Ciprofloxacin Label ), LISINOPRIL (20 Mg, Unk) (View Lisinopril Review and Lisinopril Label ), METOCLOPRAMIDE HYDROCHLORIDE (10 Mg, Unk) (View Metoclopramide Hydrochloride Review and Metoclopramide Hydrochloride Label ), SIMVASTATIN (10 Mg, Unk) (View Simvastatin Review and Simvastatin Label ). Patient was hospitalized.

6683547-7 | Bradycardia, Cholestasis, Confusional State, Cyanosis, Cytolytic Hepatitis, Dehydration, Diarrhoea, Escherichia Urinary Tract Infection, Hepatic Steatosis
on Mar 31, 2010 Female patient from FRANCE , 73 years of age, weighting 94.80 lb, was diagnosed with breast cancer (What is breast cancer?) and was treated with Vinorelbine (View Usage). After Vinorelbine was administered, patient had the following side effects: bradycardia, cholestasis, confusional state, cyanosis, cytolytic hepatitis, dehydration, diarrhoea, escherichia urinary tract infection, hepatic steatosis. Vinorelbine dosage: 32 Mg Iv. During the same period patient was treated with LAPATINIB (1250 Mg Po) (View Lapatinib Review and Lapatinib Label ), TAREG (View Tareg Review and Tareg Label ), CORTANCYL. MFR: NOT SPECIFIED (View Cortancyl. Mfr: Not Specified Review and Cortancyl. Mfr: Not Specified Label ), STILNOX. MFR: NOT SPECIFIED (View Stilnox. Mfr: Not Specified Review and Stilnox. Mfr: Not Specified Label ), ZOMETA (View Zometa Review and Zometa Label ), ALPRAZOLAM (View Alprazolam Review and Alprazolam Label ). Patient was hospitalized.

6679191-8 | Abdominal Pain, Confusional State, Dehydration, Diarrhoea, Hypothermia, Nausea, Neutropenia, Performance Status Decreased
Patient was taking Vinorelbine (View Usage). Patient experienced the following unwanted or unexpected effects: abdominal pain (What is abdominal pain?), confusional state, dehydration, diarrhoea, hypothermia (What is hypothermia?), nausea (What is nausea?), neutropenia, performance status decreased on Mar 26, 2010 from FRANCE Additional patient health information: Female patient , 73 years of age, weighting 94.80 lb, was diagnosed with breast cancer (What is breast cancer?) and. Vinorelbine dosage: 32 Mg Iv. During the same period patient was treated with LAPATINIB (1250 Mg Po) (View Lapatinib Review and Lapatinib Label ), TAREG (View Tareg Review and Tareg Label ), CORTANCYL (View Cortancyl Review and Cortancyl Label ), ZOLPIDEM (View Zolpidem Review and Zolpidem Label ), SOMETA (View Someta Review and Someta Label ), ALPRAZOLAM (View Alprazolam Review and Alprazolam Label ). Patient was hospitalized.

6674240-5 | Abdominal Pain, Confusional State, Dehydration, Diarrhoea, Hypothermia, Nausea, Neutropenia, Performance Status Decreased, Septic Shock
Adverse event was reported on Mar 12, 2010 by a Female patient taking Vinorelbine (View Usage) (Dosage: 22.5 Mg/m2 Iv) was diagnosed with breast cancer (What is breast cancer?) and. Location: FRANCE , 73 years of age, weighting 94.80 lb, Patient had the following side effects: abdominal pain (What is abdominal pain?), confusional state, dehydration, diarrhoea, hypothermia (What is hypothermia?), nausea (What is nausea?), neutropenia, performance status decreased, septic shock. During the same period patient was treated with LAPATINIB (1250 Mg Po) (View Lapatinib Review and Lapatinib Label ), TAREG (View Tareg Review and Tareg Label ), CORTANCYL (View Cortancyl Review and Cortancyl Label ), ZOLPIDEM (View Zolpidem Review and Zolpidem Label ), ZOMETA (View Zometa Review and Zometa Label ), ALPRAZOLAM (View Alprazolam Review and Alprazolam Label ). Patient was hospitalized.

6662224-2 | Interstitial Lung Disease
on Mar 22, 2010 Male patient from UNITED KINGDOM , 74 years of age, was diagnosed with lung neoplasm malignant and was treated with Vinorelbine (View Usage). After Vinorelbine was administered, patient had the following side effects: interstitial lung disease. Vinorelbine dosage: 15 Mg, Unk. During the same period patient was treated with CISPLATIN (50 Mg, Unk) (View Cisplatin Review and Cisplatin Label ).

6662222-9 | Abdominal Pain, Clostridial Infection, Diarrhoea, Hypotension, Megacolon, Multi-organ Failure, Septic Shock, Urine Output Decreased
on Mar 24, 2010 Female patient from UNITED KINGDOM , 63 years of age, was diagnosed with breast cancer metastatic, disease progression and was treated with Vinorelbine (View Usage). Patient experienced the following unwanted or unexpected effects: abdominal pain (What is abdominal pain?), clostridial infection, diarrhoea, hypotension, megacolon, multi-organ failure, septic shock, urine output decreased. Vinorelbine dosage: . During the same period patient was treated with TRASTUZUMAB (View Trastuzumab Review and Trastuzumab Label ).

6660485-7 | Confusional State, Dehydration, Diarrhoea, Hypothermia, Nausea, Neutropenia, Performance Status Decreased
Patient was taking Vinorelbine (View Usage). Patient had the following side effects: confusional state, dehydration, diarrhoea, hypothermia (What is hypothermia?), nausea (What is nausea?), neutropenia, performance status decreased on Mar 12, 2010 from FRANCE Additional patient health information: Female patient , 73 years of age, weighting 94.80 lb, was diagnosed with breast cancer (What is breast cancer?) and. Vinorelbine dosage: 22.5 Mg/m2 Iv. During the same period patient was treated with LAPATINIB (1250 Mg Po) (View Lapatinib Review and Lapatinib Label ), TAREG (View Tareg Review and Tareg Label ), CORTANCYL. MFR: NOT SPECIFIED (View Cortancyl. Mfr: Not Specified Review and Cortancyl. Mfr: Not Specified Label ), STILNOX. MFR: NOT SPECIFIED (View Stilnox. Mfr: Not Specified Review and Stilnox. Mfr: Not Specified Label ), ZOMETA (View Zometa Review and Zometa Label ), ALPRAZOLAM (View Alprazolam Review and Alprazolam Label ). Patient was hospitalized.

6509840-6 | Cardiovascular Insufficiency, Condition Aggravated, Diarrhoea, Electrolyte Imbalance, Febrile Neutropenia, Hypovolaemia, No Therapeutic Response, Pancytopenia, Pulmonary Embolism
Adverse event was reported on Dec 07, 2009 by a Male patient taking Vinorelbine (View Usage) (Dosage: 40 Mg;iv) was diagnosed with lung neoplasm malignant and. Location: DENMARK , 60 years of age, After Vinorelbine was administered, patient had the following side effects: cardiovascular insufficiency, condition aggravated, diarrhoea, electrolyte imbalance, febrile neutropenia, hypovolaemia, no therapeutic response, pancytopenia, pulmonary embolism (What is pulmonary embolism?). During the same period patient was treated with SINPLATIN (View Sinplatin Review and Sinplatin Label ).

6485106-8 | Neutropenic Sepsis
on Nov 17, 2009 Female patient from GERMANY , 59 years of age, was diagnosed with non-small cell lung cancer and was treated with Vinorelbine (View Usage). Patient experienced the following unwanted or unexpected effects: neutropenic sepsis. Vinorelbine dosage: 30 Mg/m2, Intravenous. During the same period patient was treated with CISPLATIN (80 Mg/m2, Intravenous) (View Cisplatin Review and Cisplatin Label ).

6476532-1 | Neutropenic Sepsis
on Nov 18, 2009 Female patient from UNITED KINGDOM , 69 years of age, was diagnosed with non-small cell lung cancer and was treated with Vinorelbine (View Usage). Patient had the following side effects: neutropenic sepsis. Vinorelbine dosage: 30 Mg/m2, Day, Intravenous. During the same period patient was treated with CISPLATIN (80 Mg/m2, Day, Intravenous) (View Cisplatin Review and Cisplatin Label ).

6476513-8 | Chest Pain, Lobar Pneumonia, Malaise, Neutropenic Sepsis, Rectal Haemorrhage
Patient was taking Vinorelbine (View Usage). After Vinorelbine was administered, patient had the following side effects: chest pain (What is chest pain?), lobar pneumonia, malaise, neutropenic sepsis, rectal haemorrhage on Nov 17, 2009 from UNITED KINGDOM Additional patient health information: Female patient , 62 years of age, was diagnosed with non-small cell lung cancer and. Vinorelbine dosage: 30 Mg/m2, Intravenous. During the same period patient was treated with CISPLATIN (80 Mg/m2, Intravenous) (View Cisplatin Review and Cisplatin Label ). Patient was hospitalized.

6472413-8 | Gastrointestinal Disorder, Neutropenic Sepsis, Pancreatitis
Adverse event was reported on Nov 16, 2009 by a Female patient taking Vinorelbine (View Usage) (Dosage: 30 Mg;m**2;iv) was diagnosed with lung neoplasm malignant and. Location: UNITED KINGDOM , 72 years of age, Patient experienced the following unwanted or unexpected effects: gastrointestinal disorder, neutropenic sepsis, pancreatitis. During the same period patient was treated with CISPLATIN (View Cisplatin Review and Cisplatin Label ).

6467525-9 | Adrenal Disorder, Metastasis, Neutropenic Sepsis
on Nov 16, 2009 Female patient from UNITED KINGDOM , 59 years of age, was diagnosed with non-small cell lung cancer and was treated with Vinorelbine (View Usage). Patient had the following side effects: adrenal disorder, metastasis, neutropenic sepsis. Vinorelbine dosage: 30 Mg/m**2; Iv. During the same period patient was treated with CISPLATIN (View Cisplatin Review and Cisplatin Label ).

6467129-8 | Neutropenic Sepsis
on Nov 16, 2009 Female patient from DENMARK , 69 years of age, was diagnosed with non-small cell lung cancer and was treated with Vinorelbine (View Usage). After Vinorelbine was administered, patient had the following side effects: neutropenic sepsis. Vinorelbine dosage: 30 Mg/m**2; Iv. During the same period patient was treated with CISPLATIN (View Cisplatin Review and Cisplatin Label ).

6465821-2 | Chest Pain, Malaise, Neutropenic Sepsis, Pneumonia, Rectal Haemorrhage
Patient was taking Vinorelbine (View Usage). Patient experienced the following unwanted or unexpected effects: chest pain (What is chest pain?), malaise, neutropenic sepsis, pneumonia (What is pneumonia?), rectal haemorrhage on Nov 18, 2009 from UNITED KINGDOM Additional patient health information: Female patient , 62 years of age, was diagnosed with non-small cell lung cancer and. Vinorelbine dosage: 30 Mg/m2, Q21 Days, Iv. During the same period patient was treated with CISPLATIN (80 Mg/m2, Q3 Weeks, Iv) (View Cisplatin Review and Cisplatin Label ). Patient was hospitalized.

6465660-2 | Adrenocortical Insufficiency Acute, Renal Failure Acute
Adverse event was reported on Nov 18, 2009 by a Male patient taking Vinorelbine (View Usage) (Dosage: 30 Mg/m2, Q21 Days, Iv) was diagnosed with non-small cell lung cancer and. Location: UNITED KINGDOM , 64 years of age, Patient had the following side effects: adrenocortical insufficiency acute, renal failure acute. During the same period patient was treated with CARBOPLATIN (Q21 Days,) (View Carboplatin Review and Carboplatin Label ).

6465510-4 | Adrenocortical Insufficiency Acute, Haemodialysis, Renal Failure Acute
on Nov 13, 2009 Male patient from DENMARK , 64 years of age, was diagnosed with non-small cell lung cancer and was treated with Vinorelbine (View Usage). After Vinorelbine was administered, patient had the following side effects: adrenocortical insufficiency acute, haemodialysis, renal failure acute. Vinorelbine dosage: 30 Mg/m**2; Iv. During the same period patient was treated with CARBOPLATIN (View Carboplatin Review and Carboplatin Label ). Patient was hospitalized.

6444484-6 | Catheter Site Erythema, Catheter Site Pain, Neutrophil Count Decreased, Pyrexia
on Nov 17, 2009 Female patient from UNITED STATES , weighting 187.2 lb, was diagnosed with breast cancer metastatic and was treated with Vinorelbine (View Usage). Patient experienced the following unwanted or unexpected effects: catheter site erythema, catheter site pain, neutrophil count decreased, pyrexia. Vinorelbine dosage: Vinorelbine 20mg Weekly X 3 Weeks/m Iv Bolus. During the same period patient was treated with MYLANTA (View Mylanta Review and Mylanta Label ), NEURONTIN (View Neurontin Review and Neurontin Label ), PRILOSEC (View Prilosec Review and Prilosec Label ), TUMS (View Tums Review and Tums Label ), VITAMIN B COMPLEX CAP (View Vitamin B Complex Cap Review and Vitamin B Complex Cap Label ), ZOFRAN (View Zofran Review and Zofran Label ), COMPAZINE (View Compazine Review and Compazine Label ), KAPIDEX (View Kapidex Review and Kapidex Label ). Patient was hospitalized.

6375987-0 | Neutropenic Sepsis
Patient was taking Vinorelbine (View Usage). Patient had the following side effects: neutropenic sepsis on Sep 07, 2009 from UNITED KINGDOM Additional patient health information: Male patient , 54 years of age, . Vinorelbine dosage: . During the same period patient was treated with CISPLATIN (View Cisplatin Review and Cisplatin Label ), CETUXIMAB (View Cetuximab Review and Cetuximab Label ). Patient was hospitalized.

6359321-8 | Neutropenia, Pneumonia, Thrombocytopenia
Adverse event was reported on Aug 28, 2009 by a Male patient taking Vinorelbine (View Usage) (Dosage: 20 Mg/m2 Unk Iv) was diagnosed with acute myeloid leukaemia, burkitt's lymphoma and. Location: UNITED KINGDOM , 31 years of age, After Vinorelbine was administered, patient had the following side effects: neutropenia, pneumonia (What is pneumonia?), thrombocytopenia. During the same period patient was treated with GEMCITABINE (3600 Mg/m2 Iv) (View Gemcitabine Review and Gemcitabine Label ), TOPOTECAN (1 Mg/m2 Iv) (View Topotecan Review and Topotecan Label ), THIOTEPA (15 Mg/m2 Iv) (View Thiotepa Review and Thiotepa Label ), DEXAMETHASONE 4MG TAB (View Dexamethasone 4mg Tab Review and Dexamethasone 4mg Tab Label ), NEUPOGEN (View Neupogen Review and Neupogen Label ).

6337436-8 | Heart Rate Increased, Hypertension
on Sep 01, 2009 Female patient from UNITED STATES , 54 years of age, weighting 211.6 lb, was diagnosed with breast cancer metastatic and was treated with Vinorelbine (View Usage). Patient experienced the following unwanted or unexpected effects: heart rate increased, hypertension. Vinorelbine dosage: 20mg/m2 Weekly Iv Bolus. Patient was hospitalized.

6206602-4 | Activated Partial Thromboplastin Time Prolonged, Incorrect Dose Administered, Prothrombin Time Prolonged
on May 27, 2009 Female patient from UNITED STATES , weighting 149.0 lb, was diagnosed with breast cancer metastatic and was treated with Vinorelbine (View Usage). Patient had the following side effects: activated partial thromboplastin time prolonged, incorrect dose administered, prothrombin time prolonged. Vinorelbine dosage: 25mg/m2 Weekly X 3 Weeks/m Iv. During the same period patient was treated with SORAFENIB 200MG BAYER (200mg Daily Po) (View Sorafenib 200mg Bayer Review and Sorafenib 200mg Bayer Label ), ATENOLOL (View Atenolol Review and Atenolol Label ), CARTIA XT (View Cartia Xt Review and Cartia Xt Label ), COUMADIN (View Coumadin Review and Coumadin Label ).

6202580-2 | Activated Partial Thromboplastin Time Prolonged, Incorrect Dose Administered, Prothrombin Time Prolonged
Patient was taking Vinorelbine (View Usage). After Vinorelbine was administered, patient had the following side effects: activated partial thromboplastin time prolonged, incorrect dose administered, prothrombin time prolonged on May 21, 2009 from UNITED STATES Additional patient health information: Female patient , weighting 149.0 lb, was diagnosed with breast cancer metastatic and. Vinorelbine dosage: 25mg/m2 Weekly X 8 Weeks/m Iv. During the same period patient was treated with SORAFENIB 200MG BAYER (Sorafenib 200gm Daily Po) (View Sorafenib 200mg Bayer Review and Sorafenib 200mg Bayer Label ).

6190796-3 | Activated Partial Thromboplastin Time Prolonged, Blood Pressure Increased, Contusion, Pain, Prothrombin Time Prolonged, Swelling
Adverse event was reported on May 13, 2009 by a Female patient taking Vinorelbine (View Usage) (Dosage: 25 Mg/m2 Weeklyx3 Weeks/mon Iv) was diagnosed with breast cancer metastatic and. Location: UNITED STATES , weighting 149.0 lb, Patient experienced the following unwanted or unexpected effects: activated partial thromboplastin time prolonged, blood pressure increased, contusion, pain (What is pain?), prothrombin time prolonged, swelling. During the same period patient was treated with SORAFENIB 200MG BAYER (Sorafenib 200mg Daily Po) (View Sorafenib 200mg Bayer Review and Sorafenib 200mg Bayer Label ), LORSARTAN (View Lorsartan Review and Lorsartan Label ), ATENOLOL (View Atenolol Review and Atenolol Label ), CARTIA XT (View Cartia Xt Review and Cartia Xt Label ).

6177384-X | Constipation, Pneumatosis Intestinalis, Pneumoperitoneum
on May 01, 2009 Female patient from FRANCE , 53 years of age, was diagnosed with metastasis and was treated with Vinorelbine (View Usage). Patient had the following side effects: constipation (What is constipation?), pneumatosis intestinalis, pneumoperitoneum. Vinorelbine dosage: . During the same period patient was treated with (CORTICOSTEROIDS) (View (corticosteroids) Review and (corticosteroids) Label ), METASTASIS (METASTASIS) (View Metastasis (metastasis) Review and Metastasis (metastasis) Label ), 5 FLUOROURACIL (VINORELBINE) (View 5-fluorouracil (vinorelbine) Review and 5-fluorouracil (vinorelbine) Label ). Patient was hospitalized.

6164188-7 | Metastases To Lung, Multiple Myeloma
on Apr 02, 2009 Male patient from GREECE , 67 years of age, was diagnosed with lung adenocarcinoma and was treated with Vinorelbine (View Usage). After Vinorelbine was administered, patient had the following side effects: metastases to lung, multiple myeloma (What is multiple myeloma?). Vinorelbine dosage: . During the same period patient was treated with TOPOTECAN (TOPOTECAN) (View Topotecan (topotecan) Review and Topotecan (topotecan) Label ), CISPLATIN (View Cisplatin Review and Cisplatin Label ), DOCETAXEL (View Docetaxel Review and Docetaxel Label ).

6154983-2 | Constipation, Pneumatosis Intestinalis
Patient was taking Vinorelbine (View Usage). Patient experienced the following unwanted or unexpected effects: constipation (What is constipation?), pneumatosis intestinalis on Mar 31, 2009 from FRANCE Additional patient health information: Female patient , 53 years of age, was diagnosed with metastasis and. Vinorelbine dosage: . During the same period patient was treated with CORTICOSTEROIDS (View Corticosteroids Review and Corticosteroids Label ), 5 FLUOROURACIL /00098801/ (View 5-fluorouracil /00098801/ Review and 5-fluorouracil /00098801/ Label ). Patient was hospitalized.

6121532-4 | Rash, Renal Failure Acute, Vasculitis
Adverse event was reported on Mar 05, 2009 by a Female patient taking Vinorelbine (View Usage) (Dosage: 38 Mg, Single Dose, Intravenous) was diagnosed with non-small cell lung cancer and. Location: , 63 years of age, weighting 121.3 lb, Patient had the following side effects: rash (What is rash?), renal failure acute, vasculitis (What is vasculitis?). During the same period patient was treated with CEFTRIAXONE FOR INJECTION (CEFTRIAXONE) (View Ceftriaxone For Injection (ceftriaxone) Review and Ceftriaxone For Injection (ceftriaxone) Label ), CIPROFLOXACIN (View Ciprofloxacin Review and Ciprofloxacin Label ), CISPLATIN (View Cisplatin Review and Cisplatin Label ), CLARITHROMYCIN (View Clarithromycin Review and Clarithromycin Label ), (DEXAMFTHASONE) (View (dexamfthasone) Review and (dexamfthasone) Label ), GENTAMICIN (View Gentamicin Review and Gentamicin Label ), (TAZOCIN) (View (tazocin) Review and (tazocin) Label ). Patient was hospitalized and became disabled.

6119664-X | Neutropenic Sepsis
on Mar 03, 2009 Female patient from UNITED KINGDOM , 49 years of age, weighting 127.9 lb, was diagnosed with non-small cell lung cancer and was treated with Vinorelbine (View Usage). After Vinorelbine was administered, patient had the following side effects: neutropenic sepsis. Vinorelbine dosage: 42 Mg, Intravenous, 100 Mg Intravenous. During the same period patient was treated with CISPLATIN (125 Mg Intravenous) (View Cisplatin Review and Cisplatin Label ), CITALOPRAM HYDROBROMIDE (View Citalopram Hydrobromide Review and Citalopram Hydrobromide Label ). Patient was hospitalized.

6078516-4 | Diarrhoea, Pyrexia
on Feb 11, 2009 Female patient from UNITED STATES , 48 years of age, weighting 222.0 lb, was diagnosed with breast cancer metastatic and was treated with Vinorelbine (View Usage). Patient experienced the following unwanted or unexpected effects: diarrhoea, pyrexia. Vinorelbine dosage: 25mg/kg Every Two Weeks Iv Bolus. During the same period patient was treated with AVASTIN (10mg/kg Weekly Iv Drip) (View Avastin Review and Avastin Label ), TRASTUZUMAB (2mg/kg Weekly Iv Drip) (View Trastuzumab Review and Trastuzumab Label ). Patient was hospitalized.

6062803-X | Neutrophil Count Decreased, White Blood Cell Count Decreased
Patient was taking Vinorelbine (View Usage). Patient had the following side effects: neutrophil count decreased, white blood cell count decreased on Feb 02, 2009 from UNITED STATES Additional patient health information: Female patient , 48 years of age, weighting 222.0 lb, was diagnosed with breast cancer metastatic and. Vinorelbine dosage: 25mg/kg Every Two Weeks Iv Bolus. During the same period patient was treated with AVASTIN (10mg/kg Weekly Iv Drip) (View Avastin Review and Avastin Label ), TRASTUZUMAB (2mg/kg Weekly Iv Drip) (View Trastuzumab Review and Trastuzumab Label ).

6046207-1 | Adrenal Insufficiency
Adverse event was reported on Jan 21, 2009 by a Female patient taking Vinorelbine (View Usage) (Dosage: 25mg/m2 Weekly Iv) was diagnosed with breast cancer (What is breast cancer?) and. Location: UNITED STATES , weighting 182.8 lb, After Vinorelbine was administered, patient had the following side effects: adrenal insufficiency. During the same period patient was treated with CLONAZEPAM (View Clonazepam Review and Clonazepam Label ), COMPAZINE (View Compazine Review and Compazine Label ), EFFEXOR XR (View Effexor Xr Review and Effexor Xr Label ), LORAZEPAM (View Lorazepam Review and Lorazepam Label ), ZESTORETIC (View Zestoretic Review and Zestoretic Label ), LEVAQUIN (View Levaquin Review and Levaquin Label ), BEVACIZUMAB (View Bevacizumab Review and Bevacizumab Label ), HERCEPTIN (View Herceptin Review and Herceptin Label ). Patient was hospitalized.

6035495-3 | Adrenal Insufficiency, Anorexia, Blood Sodium Decreased, Diarrhoea, Fatigue, Haematocrit Decreased, Haemoglobin Decreased, Inappropriate Antidiuretic Hormone Secretion
on Jan 12, 2009 Female patient from UNITED STATES , weighting 182.8 lb, was diagnosed with breast cancer (What is breast cancer?) and was treated with Vinorelbine (View Usage). Patient experienced the following unwanted or unexpected effects: adrenal insufficiency, anorexia, blood sodium decreased, diarrhoea, fatigue, haematocrit decreased, haemoglobin decreased, inappropriate antidiuretic hormone secretion. Vinorelbine dosage: 25mg/m2 Weekly Iv. During the same period patient was treated with CLONAZEPAM (View Clonazepam Review and Clonazepam Label ), COMPAZINE (View Compazine Review and Compazine Label ), EFFEXOR XR (View Effexor Xr Review and Effexor Xr Label ), LORAZEPAM (View Lorazepam Review and Lorazepam Label ), ZESTORETIC (View Zestoretic Review and Zestoretic Label ), LEVAQUIN (View Levaquin Review and Levaquin Label ), BEVACIZUMAB (View Bevacizumab Review and Bevacizumab Label ), HERCEPTIN (View Herceptin Review and Herceptin Label ). Patient was hospitalized.

6003737-6 | Renal Failure Acute, Vasculitis
on Nov 27, 2008 Female patient from UNITED KINGDOM , 63 years of age, weighting 121.3 lb, was diagnosed with non-small cell lung cancer and was treated with Vinorelbine (View Usage). Patient had the following side effects: renal failure acute, vasculitis (What is vasculitis?). Vinorelbine dosage: 38 Mg Total Iv. During the same period patient was treated with CEFTRIAXONE (View Ceftriaxone Review and Ceftriaxone Label ), CIPROFLOXACIN HCL (View Ciprofloxacin Hcl Review and Ciprofloxacin Hcl Label ), CISPLATIN (View Cisplatin Review and Cisplatin Label ), CLARITHROMYCIN (View Clarithromycin Review and Clarithromycin Label ), DEXAMETHASONE (View Dexamethasone Review and Dexamethasone Label ), GENTAMICIN (View Gentamicin Review and Gentamicin Label ), TAZOCIN (View Tazocin Review and Tazocin Label ). Patient was hospitalized and became disabled.

5988154-7 | Infusion Site Erythema, Infusion Site Exfoliation, Infusion Site Paraesthesia, Infusion Site Pruritus, Infusion Site Reaction, Infusion Site Vesicles
Patient was taking Vinorelbine (View Usage). After Vinorelbine was administered, patient had the following side effects: infusion site erythema, infusion site exfoliation, infusion site paraesthesia, infusion site pruritus, infusion site reaction, infusion site vesicles on Dec 08, 2008 from UNITED STATES Additional patient health information: Female patient , weighting 208.8 lb, . Vinorelbine dosage: Iv.

5930702-7 | Malaise, Neutropenia, Oropharyngeal Pain, Pyrexia, Sinus Headache, Sinusitis
Adverse event was reported on Oct 24, 2008 by a Female patient taking Vinorelbine (View Usage) (Dosage: 25mg/m2 Weekly Iv) was diagnosed with breast cancer (What is breast cancer?) and. Location: UNITED STATES , weighting 182.8 lb, Patient experienced the following unwanted or unexpected effects: malaise, neutropenia, oropharyngeal pain, pyrexia, sinus headache, sinusitis (What is sinusitis?). During the same period patient was treated with CLONAZEPAM (View Clonazepam Review and Clonazepam Label ), COMPAZINE (View Compazine Review and Compazine Label ), EFFEXOR (View Effexor Review and Effexor Label ), LORAZEPAM (View Lorazepam Review and Lorazepam Label ), ZOSTORETIC (View Zostoretic Review and Zostoretic Label ), LEVAQUIN (View Levaquin Review and Levaquin Label ), BEVACIZUMAB (View Bevacizumab Review and Bevacizumab Label ), HERCOPTIN IV (View Hercoptin Iv Review and Hercoptin Iv Label ). Patient was hospitalized.

5831862-9 | Anaemia, Cardiovascular Insufficiency, Chronic Obstructive Pulmonary Disease, Gamma-glutamyltransferase Increased, Gastroenteritis Norovirus, Hypocalcaemia, Neutropenia, Night Sweats, Platelet Count Decreased
on Jul 15, 2008 Male patient from GERMANY , 57 years of age, weighting 189.6 lb, was diagnosed with non-small cell lung cancer and was treated with Vinorelbine (View Usage). Patient had the following side effects: anaemia, cardiovascular insufficiency, chronic obstructive pulmonary disease, gamma-glutamyltransferase increased, gastroenteritis norovirus, hypocalcaemia, neutropenia, night sweats, platelet count decreased. Vinorelbine dosage: 140 Mg, Intake Every Days. During the same period patient was treated with CISPLATIN (138.8 Mg, Intake Every Days) (View Cisplatin Review and Cisplatin Label ), NITROGLYCERIN (Intake Every Days) (View Nitroglycerin Review and Nitroglycerin Label ), NOVALGIN (METAMIZOLE SODIUM) (View Novalgin (metamizole Sodium) Review and Novalgin (metamizole Sodium) Label ), MORPHINE (View Morphine Review and Morphine Label ), DEXAMETHASONE SODIUM PHOSPHATE (View Dexamethasone Sodium Phosphate Review and Dexamethasone Sodium Phosphate Label ), DOPAMINE (DOPAMINE HYDROCHLORIDE, GLUCOSE) (View Dopamine (dopamine Hydrochloride, Glucose) Review and Dopamine (dopamine Hydrochloride, Glucose) Label ), LASIX (View Lasix Review and Lasix Label ), ARCOXIA (View Arcoxia Review and Arcoxia Label ).

5822606-5 | Blood Creatinine Increased, Febrile Neutropenia, Intestinal Obstruction, Nausea
on Jul 23, 2008 Female patient from UNITED STATES , weighting 157.0 lb, was diagnosed with rectal cancer and was treated with Vinorelbine (View Usage). After Vinorelbine was administered, patient had the following side effects: blood creatinine increased, febrile neutropenia, intestinal obstruction, nausea (What is nausea?). Vinorelbine dosage: 25 Mg/m2 D 1,8,15 Q 28 D Iv. During the same period patient was treated with LAPATINIB 1500MG (1500mg Daily P.o.) (View Lapatinib 1500mg Review and Lapatinib 1500mg Label ). Patient was hospitalized.

5787672-4 | Nausea, Weight Decreased
Patient was taking Vinorelbine (View Usage). Patient experienced the following unwanted or unexpected effects: nausea (What is nausea?), weight decreased on Jun 24, 2008 from UNITED STATES Additional patient health information: Male patient , 53 years of age, weighting 80.00 lb, was diagnosed with gastric cancer and. Vinorelbine dosage: 37mg D1,d8,d15 Iv. During the same period patient was treated with LAPATININB (1500mg D2-5d9-12, D16-25 Po) (View Lapatininb Review and Lapatininb Label ). Patient was hospitalized.

5775229-0 | Circulatory Collapse, Dehydration, Disease Progression, Dyspnoea, Hypertension, Metastases To Lung, Metastases To Trachea, Nausea, Oral Intake Reduced
Adverse event was reported on Jun 16, 2008 by a Male patient taking Vinorelbine (View Usage) (Dosage: 15mg/m2 (initially 25 D 1,8,15 Q 28 D Iv) was diagnosed with synovial sarcoma and. Location: UNITED STATES , weighting 198.0 lb, Patient had the following side effects: circulatory collapse, dehydration, disease progression, dyspnoea, hypertension, metastases to lung, metastases to trachea, nausea (What is nausea?), oral intake reduced. During the same period patient was treated with LAPATINIB 1500MG (1500mg Daily P.o.) (View Lapatinib 1500mg Review and Lapatinib 1500mg Label ).

5774892-8 | Disease Progression, Lung Neoplasm, Pleural Effusion, Pulmonary Embolism, Pulmonary Mass
on Jun 16, 2008 Male patient from UNITED STATES , weighting 173.7 lb, was diagnosed with transitional cell carcinoma and was treated with Vinorelbine (View Usage). After Vinorelbine was administered, patient had the following side effects: disease progression, lung neoplasm, pleural effusion, pulmonary embolism (What is pulmonary embolism?), pulmonary mass. Vinorelbine dosage: 49 Mg D1,d8,d15/cycle 042. During the same period patient was treated with LAPATINIB (1500 Mg Qd 047) (View Lapatinib Review and Lapatinib Label ), VYTORIN (View Vytorin Review and Vytorin Label ), LISINOPRIL (View Lisinopril Review and Lisinopril Label ), ATENOLOL (View Atenolol Review and Atenolol Label ).

5753667-X | Pulmonary Embolism
on May 21, 2008 Male patient from UNITED STATES , weighting 173.7 lb, was diagnosed with transitional cell carcinoma and was treated with Vinorelbine (View Usage). Patient experienced the following unwanted or unexpected effects: pulmonary embolism (What is pulmonary embolism?). Vinorelbine dosage: 49 Mg D1,d8,d15/cycle 042. During the same period patient was treated with VYTORIN (View Vytorin Review and Vytorin Label ), LISINOPRIL (View Lisinopril Review and Lisinopril Label ), ATENOLOL (View Atenolol Review and Atenolol Label ). Patient was hospitalized.

5732806-0 | Confusional State, Fatigue, Hypophosphataemia, Urinary Incontinence
Patient was taking Vinorelbine (View Usage). Patient had the following side effects: confusional state, fatigue, hypophosphataemia, urinary incontinence (What is urinary incontinence?) on May 07, 2008 from UNITED STATES Additional patient health information: Female patient , weighting 126.0 lb, was diagnosed with adenocarcinoma, metastasis and. Vinorelbine dosage: 25 Mg/m2 D 1, 8, 15 Q 28 D Iv. During the same period patient was treated with LAPATINIB (1500mg Daily P.o.) (View Lapatinib Review and Lapatinib Label ).